Atai Life Sciences N.V. (ATAI) Stock Price, Quote & News

Company Profile

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 282 0507

Website: www.ataibeckley.com

Address:

250 West 34th Street, New York, United States

OfficialStocktwitsUser Apr. 9 at 7:38 PM

$ATAI RSI: 56.17, MACD: -0.0004 Vol: 0.16, MA20: 3.61, MA50: 3.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

KeepLossesSmall Apr. 9 at 5:48 PM

$ATAI

1 · Reply

RarelyRight Apr. 9 at 4:37 PM

$DFTX I don’t get why this has run 50%+ in the last 3 months while every other psychedelic stock has been flat to down. Do I sell some and move it to $ATAI or $CMPS ?

3 · Reply

moneygrabber55 Apr. 9 at 4:04 PM

$ATAI sideways is better than down right? Can we see $6 again?

0 · Reply

DarcyF Apr. 9 at 3:19 PM

$ATAI

0 · Reply

Wallstreetiscriminal Apr. 9 at 3:15 PM

$ATAI why in the hell would it take 3 years to get top line data for this? It doesn’t take that long to do one more trial. Feels like our billionaire buddies are stringing us along setting the stage for another cash raise in the future.

1 · Reply

Burwep Apr. 9 at 2:53 PM

$ATAI why is it down with the good news? been trading sideways for 5 months…..

1 · Reply

TheVisona Apr. 9 at 1:47 PM

$ATAI

0 · Reply

soksobay Apr. 9 at 7:21 AM

$ATAI ,Help not place to be. The only 1 is Dftx

1 · Reply

PrimePorter Apr. 9 at 3:19 AM

$ATAI

0 · Reply

AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response

Apr 8, 2026, 6:00 AM EDT - 1 day ago

AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

Mar 24, 2026, 6:00 AM EDT - 16 days ago

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

Mar 10, 2026, 6:00 AM EDT - 4 weeks ago

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

Mar 6, 2026, 7:00 AM EST - 4 weeks ago

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Feb 26, 2026, 9:49 AM EST - 6 weeks ago

AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data

Feb 26, 2026, 7:00 AM EST - 6 weeks ago

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

Feb 20, 2026, 7:00 AM EST - 6 weeks ago

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

Jan 16, 2026, 7:00 AM EST - 2 months ago

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

Jan 8, 2026, 7:00 AM EST - 3 months ago

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

Dec 23, 2025, 7:00 AM EST - 3 months ago

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Nov 19, 2025, 7:32 PM EST - 5 months ago

Enhanced Fortifies Executive Leadership Team & Board of Directors

Oct 20, 2025, 5:29 PM EDT - 6 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Oct 16, 2025, 10:31 PM EDT - 6 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Oct 16, 2025, 4:12 PM EDT - 6 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

Oct 16, 2025, 4:10 PM EDT - 6 months ago

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Oct 13, 2025, 2:21 PM EDT - 6 months ago

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Sep 23, 2025, 2:50 PM EDT - 7 months ago

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Sep 23, 2025, 7:00 AM EDT - 7 months ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Aug 28, 2025, 4:05 PM EDT - 8 months ago

atai Life Sciences to Participate in September Investor Conferences

Jul 28, 2025, 10:58 AM EDT - 9 months ago

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Jul 28, 2025, 8:13 AM EDT - 9 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

RVTY

Jul 25, 2025, 4:16 PM EDT - 9 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:05 PM EDT - 9 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 1, 2025, 9:28 AM EDT - 10 months ago

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Jul 1, 2025, 6:05 AM EDT - 10 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:00 AM EDT - 10 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jun 2, 2025, 6:00 AM EDT - 11 months ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

May 29, 2025, 8:30 AM EDT - 11 months ago

atai Life Sciences to Participate in Upcoming Investor Conferences

May 20, 2025, 7:00 AM EDT - 11 months ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 14, 2025, 7:00 AM EDT - 11 months ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 13, 2025, 7:01 AM EDT - 11 months ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

Mar 11, 2025, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Feb 24, 2025, 4:10 PM EST - 1 year ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 10, 2025, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Oct 2, 2024, 9:21 AM EDT - 1 year ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS HELP DFTX

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jun 26, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 20, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

May 31, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 15, 2024, 6:59 AM EDT - 2 years ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Apr 24, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Apr 17, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Mar 28, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Mar 27, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Mar 4, 2024, 8:00 AM EST - 2 years ago

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

OfficialStocktwitsUser Apr. 9 at 7:38 PM

0 · Reply

KeepLossesSmall Apr. 9 at 5:48 PM

$ATAI

1 · Reply

RarelyRight Apr. 9 at 4:37 PM

$DFTX I don’t get why this has run 50%+ in the last 3 months while every other psychedelic stock has been flat to down. Do I sell some and move it to $ATAI or $CMPS ?

3 · Reply

moneygrabber55 Apr. 9 at 4:04 PM

$ATAI sideways is better than down right? Can we see $6 again?

0 · Reply

DarcyF Apr. 9 at 3:19 PM

$ATAI

0 · Reply

Wallstreetiscriminal Apr. 9 at 3:15 PM

1 · Reply

Burwep Apr. 9 at 2:53 PM

$ATAI why is it down with the good news? been trading sideways for 5 months…..

1 · Reply

TheVisona Apr. 9 at 1:47 PM

$ATAI

0 · Reply

soksobay Apr. 9 at 7:21 AM

$ATAI ,Help not place to be. The only 1 is Dftx

1 · Reply

PrimePorter Apr. 9 at 3:19 AM

$ATAI

0 · Reply

TheVisona Apr. 9 at 12:05 AM

$ATAI Patience is the game and fortunes to those who can wait. 👍

0 · Reply

GeorgeJetson17 Apr. 9 at 12:02 AM

$ATAI The Phase 2a results today were significant. Before, there was a question about whether patients would need to stop their SSRI use before using BPL003, which would have reduced the TAM.

0 · Reply

Sailingsoon Apr. 8 at 8:12 PM

$ATAI I was considering this morning after the 20+ % in Europe to take some gains but decided against it and bought more after it trended closer to my average. I have a solid position and reading it again I felt I have done the right thing for me and my family https://www.investing.com/news/analyst-ratings/deutsche-bank-initiates-atai-life-sciences-stock-at-buy-on-psychedelic-therapy-potential-93CH-4584262

0 · Reply

Framingtheworld Apr. 8 at 8:07 PM

$ATAI just let her gooooo!

0 · Reply

focafoca99 Apr. 8 at 7:54 PM

$ATAI reported Phase 2a data showing rapid and durable antidepressant responses for BPL-003 in treatment-resistant depression patients on SSRIs.

0 · Reply

mwhite9869 Apr. 8 at 7:52 PM

$ATAI down more than .50$ from PM. This manipulation shit is getting old...

0 · Reply

Sailingsoon Apr. 8 at 6:11 PM

$ATAI https://psychedelicalpha.com/resources/psychedelic-readout-tracker/ Nice overview

0 · Reply

Framingtheworld Apr. 8 at 6:06 PM

$ATAI so $DFTX hits new 52 week high. $ATAI is down 50% from high and $HELP hit new 52 week low. What gives??

2 · Reply

Hanaleimike Apr. 8 at 5:10 PM

$ATAI why were we Up to 4.24$ premarket? Can someone please tell me again how billionaires are not manipulating this stock?

1 · Reply

FastMny Apr. 8 at 4:07 PM

$ATAI had to grab a few shares today. Moving on the Phase 3. FDA in our corner.

1 · Reply

basssque Apr. 8 at 4:06 PM

$ATAI https://www.benzinga.com/news/health-care/26/04/51706084/ataibeckley-depression-drug-delivers-rapid-day-2-antidepressant-response

0 · Reply

moneygrabber55 Apr. 8 at 3:41 PM

$ATAI same shit, different day

0 · Reply

Market Cap	1.25B
Revenue (ttm)	310,000.00
Net Income (ttm)	-149.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-48,151.61%
Debt to Equity Ratio	0.00

Volume	10,284,041
Avg Vol	5,985,524
Day's Range	N/A - N/A
Shares Out	233.78M
Stochastic %K	10%
Beta	1.59
Analysts	Strong Sell
Price Target	$12.12